DEF 14C: Resonate Blends to Rebrand as Apollo Biowellness, Increases Preferred Stock Authorization

Resonate Blends, Inc. announces a corporate name change to Apollo Biowellness, Inc. and an increase in authorized preferred stock from 10 million to 75 million shares, approved by a majority shareholder via written consent.

Summary

• Resonate Blends, Inc. is changing its name to Apollo Biowellness, Inc.
• The company is increasing its authorized preferred stock from 10 million to 75 million shares.
• These changes were approved by the holder of 94.79% of the company's voting power via written consent on June 27, 2024, in lieu of a special meeting of shareholders.
• The changes will become effective on or about August 6, 2024, at least 20 days after the information statement is distributed to shareholders.
• The company believes the name change reflects its broadened business plan following the acquisition of Emergent Health Corp. (EMGE).
• The increase in authorized preferred stock is intended to maintain the company's financing and capital-raising ability.
• Shareholders are not required to take any action and should retain their existing stock certificates.

Sentiment

Score: 6

Explanation: The document outlines strategic changes aimed at positioning the company for future growth. While the potential for anti-takeover measures exists, the overall tone is moderately positive, focusing on financing and business expansion.

Positives

• The name change is intended to better reflect the company's broadened business plan after acquiring Emergent Health Corp. (EMGE).
• Increasing authorized preferred stock provides the company with greater flexibility for future financing and potential acquisitions.
• The company is positioning itself to be a leader in the field of Regenerative Medicine.

Negatives

• The increase in authorized preferred stock could potentially be used to delay or prevent a change in control of the company, although management states this is not the intention.
• The name change will require approval by FINRA and will result in a change in the CUSIP number and trading symbol of the company's common stock.

Risks

• The potential for the increased authorized preferred stock to be used as an anti-takeover device, even though management denies this intention.
• The risk that FINRA may not approve the corporate name change in a timely manner.
• The risk that the company may not be able to successfully integrate Emergent Health Corp. (EMGE) and execute its broadened business plan.

Future Outlook

The company anticipates that the name change and increase in authorized preferred stock will support its future financing and acquisition activities, positioning it as a leader in regenerative medicine.

Management Comments

• The Board of Directors believes that it is in the best interest of the shareholders to change the corporate name of the Company.
• The Board of Directors believes the increase in authorized preferred stock is necessary and advisable in order to maintain the Company's financing and capital-raising ability.

Industry Context

The company's focus on regenerative medicine aligns with a growing trend in the healthcare industry towards innovative therapies and nutritionally designed products. The acquisition of Emergent Health Corp. (EMGE) and the rebranding to Apollo Biowellness suggest a strategic shift to capitalize on this trend.

Comparison to Industry Standards

• Many companies in the biotech and wellness sectors rebrand to reflect strategic shifts, similar to Resonate Blends' move to Apollo Biowellness.
• Increasing authorized shares is a common practice for companies seeking to raise capital for growth, acquisitions, or other strategic initiatives.
• Comparable companies that have increased authorized shares include [hypothetical company 1] and [hypothetical company 2], which saw [hypothetical result 1] and [hypothetical result 2] respectively.

Stakeholder Impact

• Shareholders will see a change in the company's name and potentially experience dilution if additional preferred shares are issued.
• Employees may experience changes related to the company's new branding and strategic direction.
• Customers may see new products and services related to the company's focus on regenerative medicine.
• Suppliers and creditors may be affected by the company's potential financing activities and acquisitions.

Next Steps

• File the Certificate of Amendment with the Nevada Secretary of State.
• Obtain FINRA approval for the corporate name change.
• File a Current Report on Form 8-K with the SEC to announce the effective date of the corporate name change and the new CUSIP number.
• Potentially issue additional shares of preferred stock for financing or acquisition purposes.

Key Dates

Keywords

Apollo Biowellness, Resonate Blends, preferred stock, corporate name change, authorized shares, Emergent Health Corp, regenerative medicine, financing, capital raising